Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration

To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD). Multicenter, prospective, randomized, double-masked clinical trial with initial 12-week fi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Jg. 118; H. 6; S. 1089
Hauptverfasser:	Brown, David M, Heier, Jeffrey S, Ciulla, Thomas, Benz, Matthew, Abraham, Prema, Yancopoulos, George, Stahl, Neil, Ingerman, Avner, Vitti, Robert, Berliner, Alyson J, Yang, Ke, Nguyen, Quan Dong
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.06.2011
Schlagworte:	Aged Aged, 80 and over Choroidal Neovascularization - diagnosis Choroidal Neovascularization - etiology Choroidal Neovascularization - prevention & control Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Fovea Centralis - drug effects Fovea Centralis - pathology Humans Intravitreal Injections Male Middle Aged Prospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - administration & dosage Vascular Endothelial Growth Factor A - therapeutic use Visual Acuity Wet Macular Degeneration - complications Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
ISSN:	1549-4713, 1549-4713
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!